Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | THPO | P40225 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | THRB | P10828 | 3/20 | 0.67 |
| ▸ | BLM | P54132 | 3/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | GMNN | O75496 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodomethane SCHEMBL2339134 | 0.97 | CYP2D6 (0.67) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| Bromomethane SCHEMBL9201237 | 0.97 | CYP2D6 (0.67) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL17294730 | 0.87 | CYP2D6 (0.68) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL17294776 | 0.87 | CYP2D6 (0.68) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL17294736 | 0.87 | CYP2D6 (0.68) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL16789090 | 0.85 | MEN1 (0.57) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| Hydrochloric Acid SCHEMBL28125818 | 0.84 | MEN1 (0.59) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL24671171 | 0.83 | CYP2D6 (1.00) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL5072788 | 0.83 | CHRM2 (0.70) | CYP1A2NFKB1HIF1ALMNABLM | |
| SCHEMBL10517998 | 0.83 | CYP2D6 (0.60) | CYP2D6HTTCYP1A2CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817034-A1 | M1 AND/OR M3 RECEPTOR ANTAGONISTS IN COMBINATION WITH OTHER ACTIVES FOR TREATING RESPIRATORY DISORDERS | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006047427-A1 | M1 AND/OR M3 RECEPTOR ANTAGONISTS IN COMBINATION WITH OTHER ACTIVES FOR TREATING RESPIRATORY DISORDERS | SCHERING CORPORATION (US) | 2006-05-04 | — | — | WO | claimed |
| US-5153205-A | Administering cholinergic M3 receptor antagonist along with cholinomimetic agent | MERCK & CO., INC. (US) | 1992-10-06 | — | — | US | claimed |
| EP-0479524-A1 | Method to reduce intraocular pressure without causing miosis | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | claimed |
| EP-3310336-B1 | OPHTHALMOLOGICAL COMPOSITION COMPRISING ACECLIDINE AND MANNITOL FOR USE IN THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260069533-A1 | METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12533347-B2 | Compositions and methods for storage stable ophthalmic drugs | LENZ THERAPEUTICS OPERATIONS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4563162-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | Lenz Therapeutics Operations, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4552651-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | Lenz Therapeutics Operations, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-3542798-B1 | ACECLIDINE FOR USE IN THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12128036-B2 | Compositions and methods for storage stable ophthalmic drugs | LENZ THERAPEUTICS OPERATIONS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4385521-A2 | STORAGE STABLE COMPOSITIONS AND METHODS FOR THE TREATMENT OF REFRACTIVE ERRORS OF THE EYE | Lenz Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20020183241-A1 | Methods for treating vertigo and motion sickness using descarboethoxyloratadine | SEPRACOR INC. | 2002-12-05 | — | — | US | disclosed |
| EP-0975344-A1 | USE OF DESCARBOETHOXYLORATADINE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF URINARY INCONTINENCE, MOTION SICKNESS AND VERTIGO | SEPRACOR, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5939426-A | ALSO FOR MOTION SICKNESS AND VERTIGO | SEPRACOR INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998037889-A1 | USE OF DESCARBOETHOXYLORATADINE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF URINARY INCONTINENCE, MOTION SICKNESS AND VERTIGO | SEPRACOR, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| US-5153205-A | Administering cholinergic M3 receptor antagonist along with cholinomimetic agent | MERCK & CO., INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5153205-A | Administering cholinergic M3 receptor antagonist along with cholinomimetic agent | MERCK & CO., INC. (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0479524-A1 | Method to reduce intraocular pressure without causing miosis | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | disclosed |
| EP-0479524-A1 | Method to reduce intraocular pressure without causing miosis | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069533-A1 | METHODS FOR THE TREATMENT OF PRESBYOPIA | CHRM2, ADRB2, CHRM3 | CYP2D6 1702/4885HTT 4490/4885CYP1A2 669/4885 |
| US-20020183241-A1 | Methods for treating vertigo and motion sickness using descarboethoxyloratadine | SLC26A4, AVPR2, AVPR1B | CYP2D6 1304/4885HTT 1334/4885CYP1A2 4082/4885 |
| US-12533347-B2 | Compositions and methods for storage stable ophthalmic drugs | PDE6C, PDE6A, PDE6B | CYP2D6 1768/4885HTT 3821/4885CYP1A2 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.